@article{Ghandili_Lindhauer_Pischke_zur Wiesch_von Kroge_Polywka_Bokemeyer_Fiedler_Kröger_Ayuk_Adjallé_Modemann_2022, place={Pavia, Italy}, title={Clinical features of hepatitis E infections in patients with hematologic disorders}, volume={107}, url={https://haematologica.org/article/view/haematol.2022.280853}, DOI={10.3324/haematol.2022.280853}, abstractNote={<p>Hepatitis E virus is increasingly being reported to cause chronic infection in immunocompromised patients. However, less is known about patients with an underlying hematologic disease. In particular, the impact of hepatitis E infection on oncological therapy has been poorly described. In this retrospective single-center study, we analyzed 35 hematologic patients with hepatitis E, including 20 patients under active oncological treatment and 15 patients who were in the posttreatment follow-up or under active surveillance. The primary aim was to describe the clinical courses with particular focus on any hepatitis E-related therapy modifications of cancer-directed therapy. In the majority (60%) of patients who were under active oncological treatment, hepatitis E-related therapy modifications were made, and 25% of deaths were due to progression of the hematologic disease. In patients receiving concomitant oncological treatment, no hepatitis Erelated deaths occurred. In contrast, two patients in the follow-up group died from hepatitis E-associated acute-onchronic liver failure. Chronic hepatitis E was observed in 34% of all cases and 43% received ribavirin therapy; of those, 27% achieved a sustained virological response. CD20-directed therapy was the only independent risk factor for developing chronic hepatitis E. We conclude that CD20-directed treatment at any time point is a risk factor for developing chronic hepatitis E. Nevertheless, since mortality from the progression of hematologic disease was higher than hepatitis E-related mortality, we suggest careful case-by-case decisions on modifications of cancer treatment. Patients in the posttreatment follow-up phase may also suffer from severe courses and hepatitis E chronicity occurs as frequently as in patients undergoing active therapy.</p&gt;}, number={12}, journal={Haematologica}, author={Ghandili, Susanne and Lindhauer, Cecilia and Pischke, Sven and zur Wiesch, Julian Schulze and von Kroge, Philipp H. and Polywka, Susanne and Bokemeyer, Carsten and Fiedler, Walter and Kröger, Nicolaus and Ayuk, Francis and Adjallé, Raissa and Modemann, Franziska}, year={2022}, month={Dec.}, pages={2870-2883} }